Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

ates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (908) 938-1475, ; PaulBurroughs, Media Relations, (418) 652-8525, ext. 406, jenene.thomas@aeternazentaris.com paul.burroughs@aeternazentaris.com

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... today announced that The New England Journal ... II data for the investigational drug iniparib* (BSI-201) ... triple negative breast cancer (mTNBC) when iniparib was ...
... 2011 MiMedx Group, Inc.  (OTC Bulletin ... and marketer of patent protected biomaterial-based products, announced today ... leader in the development of tissue processing techniques for ... amnion membranes. The deal was originally announced on December ...
Cached Medicine Technology:Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 2Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 3Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 4Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 5Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 6MiMedx Completes Acquisition of Surgical Biologics 2MiMedx Completes Acquisition of Surgical Biologics 3MiMedx Completes Acquisition of Surgical Biologics 4
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
(Date:9/19/2014)... Albany,NY (PRWEB) September 19, 2014 ... Dr. Reed Ference, is excited to announce the ... with periodontal disease, gingivitis and those needing dental ... the LANAP® laser treatment removes the fear factor ... no stitches, less discomfort and bleeding make, this ...
(Date:9/19/2014)... 2014 York University researchers say a simple ... to detect heightened risk for developing Alzheimer,s disease ... telltale behavioural signs of dementia., Faculty of Health ... who led the study asked the participants to ... on dual screen laptop computers. The test aimed ...
(Date:9/19/2014)... 2014 Recent financial data reveled ... increased their sales by 7% in the last quarter ... industry can be used as a bellwether to determine ... This data has been proven to show trends with ... transportation. Other non-trucking data is largely influenced by international ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... , Recent CBO analysis ... 3 A new actuarial analysis by Oliver Wyman, Inc. ... market will be 54 percent higher than they are today ... Protection and Affordable Care Act (PPACA), excluding the impact of ...
... a new factor that is necessary for the development ... of malignant childhood brain cancer. HHMI investigator Huda Y. ... medulloblastoma from developing in mice by shutting down production ... team,s findings, reported in the December 4, 2009, issue ...
... , NEW YORK, Dec. ... H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic ... at least 6,500 fatalities. Since there is no longer ... undoubtedly understate the real situation. , (Photo: ...
... , CHICAGO, Dec. 3 An ... called platelet-rich plasma therapy (PRP), is showing strong potential ... a prominent dental researcher and editor of the ... Rutkowski, DMD, PhD, reported at the recent annual scientific ...
... low number of new cases created by a single ... as vaccination, social distancing and the use of antiviral ... the virus, suggests an epidemiological modelling study http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091807 ... Medical Association Journal ) www.cmaj.ca . ...
... ... specializing in the emerging medical travel space, announced that international medical quality authority, Dr. ... ... 2009 –- Satori World Medical, a leading global healthcare company specializing in the emerging ...
Cached Medicine News:Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4Health News:Researchers identify gene that spurs deadly brain cancer 2Health News:Researchers identify gene that spurs deadly brain cancer 3Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: